Association between paired plasma and cervicovaginal lavage fluid HIV-1 RNA levels during 36 months

Journal of Acquired Immune Deficiency Syndromes

Volumn 42, Issue 5, 2006, Pages 584-587

  Cu Uvin, Susan ^a   Snyder, Brad ^b   Harwell, Joseph I ^a   Hogan, Joseph ^b   Chibwesha, Carla ^c   Hanley, Dawn ^a   Ingersoll, Jessica ^d   Kurpewski, Jaclynn ^a   Mayer, Kenneth H ^a   Caliendo, Angela M ^d  

^a MIRIAM HOSPITAL   (United States)

^b BROWN UNIVERSITY   (United States)

^c WOMEN AND INFANTS HOSPITAL   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Blood and cervicovaginal; Female; HIV 1 RNA viral load

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA;

ADULT; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENITAL SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; NUCLEIC ACID SEQUENCE BASED AMPLIFICATION; PLASMA; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; REBOUND; VAGINAL LAVAGE; VIRUS DETECTION; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; RNA, VIRAL; STATISTICS; VAGINA; VAGINAL DOUCHING; VIRAL LOAD; VIREMIA;

EID: 33746730490     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000229997.52246.95     Document Type: Article

References (12)

1. Mofenson LM, Lambert JS, Stiehm ER, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. N Engl J Med. 1999;341:385-393.
2. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000;342:921-929.
3. Chuachoowong R, Shaffer N, Siriwasin W, et al. Short-course antenatal zidovudine reduces both cervicovaginal human immunodeficiency virus type 1 RNA levels and risk of perinatal transmission. Bangkok Collaborative Perinatal HIV Transmission Study Group. J Infect Dis. 2000;181:99-106.
4. Tuomala RE, O'Driscoll PT, Bremer JW, et al. Cell-associated genital tract virus and vertical transmission of human immunodeficiency virus type 1 in antiretroviral-experienced women. J Infect Dis. 2003;187:375-384.
5. Cu-Uvin S, Caliendo AM, Reinert S, et al. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS. 2000;14:415-421.
6. Hart CE, Lennox JL, Pratt-Palmore M, et al. Correlation of human immunodeficiency virus type 1 RNA levels in blood and the female genital tract. J Infect Dis. 1999;179:871-882.
7. Kovacs A, Wasserman SS, Burns D, et al. Determinants of HIV-1 shedding in the genital tract of women. Lancet. 2001;358:1593-1601.
8. Uvin SC, Caliendo AM. Cervicovaginal human immunodeficiency virus secretion and plasma viral load in human immunodeficiency virus-seropositive women. Obstet Gynecol. 1997;90:739-743.
9. Iversen AK, Attermann J, Gerstoft J, et al. Longitudinal and cross-sectional studies of HIV-1 RNA and DNA loads in blood and the female genital tract. Eur J Obstet Gynecol Reprod Biol. 2004;117:227-235.
10. Sullivan ST, Mandava U, Evans-Strickfaden T, et al. Diversity, divergence, and evolution of cell-free human immunodeficiency virus type 1 in vaginal secretions and blood of chronically infected women: associations with immune status. J Virol. 2005;79:9799-9809.
11. Coombs RW, Wright DJ, Reichelderfer PS, et al. Variation of human immunodeficiency virus type 1 viral RNA levels in the female genital tract: implications for applying measurements to individual women. J Infect Dis. 2001;184:1187-1191.
12. Reichelderfer PS, Coombs RW, Wright DJ, et al. Effect of menstrual cycle on HIV-1 levels in the peripheral blood and genital tract. WHS 001 Study Team. AIDS. 2000;14:2101-2107.